Proton MR spectroscopy for diagnosis and evaluation of treatment efficacy in Parkinson disease

Radiology

Volumn 278, Issue 2, 2016, Pages 505-513

  Mazuel, Leslie ^a   Chassain, Carine ^b   Jean, Betty ^b   Pereira, Bruno ^b   Cladière, Aurélie ^b   Speziale, Claudine ^b   Durif, Franck ^a,b  

^a UNIVERSITÉ CLERMONT AUVERGNE   (France)

^b SERVICE DE RHUMATOLOGIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOL METHYLTRANSFERASE INHIBITOR; CREATININE; DOPAMINE RECEPTOR STIMULATING AGENT; GLUTAMIC ACID; GLUTAMINE; INOSITOL; LEVODOPA; MONOAMINE OXIDASE INHIBITOR; N ACETYLASPARTIC ACID; ANTIPARKINSON AGENT; PROTON;

AGED; ARTICLE; BRAIN LEVEL; BRAIN METABOLISM; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIFFUSION WEIGHTED IMAGING; FEMALE; HOEHN AND YAHR SCALE; HUMAN; IMAGE ANALYSIS; IMAGE PROCESSING; IMAGE QUALITY; MALE; NUCLEAR MAGNETIC RESONANCE SCANNER; PARKINSON DISEASE; PATIENT CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTON NUCLEAR MAGNETIC RESONANCE; PUTAMEN; TREATMENT OUTCOME; UNIFIED PARKINSON DISEASE RATING SCALE; VOXEL BASED MORPHOMETRY; CASE CONTROL STUDY; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROCEDURES; REPRODUCIBILITY;

AGED; ANTIPARKINSON AGENTS; CASE-CONTROL STUDIES; FEMALE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; PARKINSON DISEASE; PROSPECTIVE STUDIES; PROTONS; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME;

EID: 84955620789     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.2015142764     Document Type: Article

References (33)

1. Chaudhuri KR, Healy DG, Schapira AH; National Institute for Clinical Excellence. Nonmotor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006;5(3):235-245.
2. Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology 2001;57(8):1497-1499.
3. Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 2008;79(4):368-376.
4. Lucetti C, Del Dotto P, Gambaccini G, et al. Proton magnetic resonance spectroscopy (1H-MRS) of motor cortex and basal ganglia in de novo Parkinson's disease patients. Neurol Sci 2001;22(1):69-70.
5. Hu MTM, Taylor-Robinson SD, Chaudhuri KR, et al. Evidence for cortical dysfunction in clinically non-demented patients with Parkinson's disease: A proton MR spectroscopy study. J Neurol Neurosurg Psychiatry 1999;67(1):20-26.
6. Camicioli RM, Korzan JR, Foster SL, et al. Posterior cingulate metabolic changes occur in Parkinson's disease patients without dementia. Neurosci Lett 2004;354(3):177-180.
7. Nie K, Zhang Y, Huang B, et al. Marked N-acetylaspartate and choline metabolite changes in Parkinson's disease patients with mild cognitive impairment. Parkinsonism Relat Disord 2013;19(3):329-334.
8. Levin BE, Katzen HL, Maudsley A, et al. Whole-brain proton MR spectroscopic imaging in Parkinson's disease. J Neuroimaging 2014;24(1):39-44.
9. Gröger A, Bender B, Wurster I, Chadzynski GL, Klose U, Berg D. Differentiation between idiopathic and atypical parkinsonian syndromes using three-dimensional magnetic resonance spectroscopic imaging. JNeurolNeurosurgPsychiatry2013;84(6):644-649.
10. Rudkin TM, Arnold DL. Proton magnetic resonance spectroscopy for the diagnosis and management of cerebral disorders. Arch Neurol 1999;56(8):919-926.
11. Abe K, Terakawa H, Takanashi M, et al. Proton magnetic resonance spectroscopy of patients with parkinsonism. Brain Res Bull 2000;52(6):589-595.
12. Davie CA, Wenning GK, Barker GJ, et al. Differentiation of multiple system atrophy from idiopathic Parkinson's disease using proton magnetic resonance spectroscopy. Ann Neurol 1995;37(2):204-210.
13. Watanabe H, Fukatsu H, Katsuno M, et al. Multiple regional 1H-MR spectroscopy in multiple system atrophy: NAA/Cr reduction in pontine base as a valuable diagnostic marker. J Neurol Neurosurg Psychiatry 2004; 75(1):103-109.
14. Kickler N, Krack P, Fraix V, et al. Glutamate measurement in Parkinson's disease using MRS at 3 T field strength. NMR Biomed 2007;20(8):757-762.
15. Emir UE, Tuite PJ, Öz G. Elevated pontine and putamenal GABA levels in mild-moderate Parkinson disease detected by 7 tesla proton MRS. PLoS ONE 2012;7(1):e30918.
16. Ellis CM, Lemmens G, Williams SCR, et al. Changes in putamen N-acetylaspartate and choline ratios in untreated and levodopatreated Parkinson's disease: A proton magnetic resonance spectroscopy study. Neurology 1997;49(2):438-444.
17. Chassain C, Bielicki G, Donnat JP, Renou JP, Eschalier A, Durif F. Cerebral glutamate metabolism in Parkinson's disease: an in vivo dynamic (13)C NMS study in the rat. Exp Neurol 2005;191(2):276-284.
18. Chassain C, Bielicki G, Durand E, et al. Metabolic changes detected by proton magnetic resonance spectroscopy in vivo and in vitro in a murin model of Parkinson's disease, the MPTP-intoxicated mouse. J Neurochem 2008;105(3):874-882.
19. Bagga P, Chugani AN, Varadarajan KS, Patel AB. In vivo NMR studies of regional cerebral energetics in MPTP model of Parkinson's disease: recovery of cerebral metabolism with acute levodopa treatment. J Neurochem 2013;127(3):365-377.
20. Chassain C, Bielicki G, Keller C, Renou JP, Durif F. Metabolic changes detected in vivo by 1H MRS in the MPTP-intoxicated mouse. NMR Biomed 2010;23(6):547-553.
21. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55(3):181-184.
22. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010;25(15):2649-2653.
23. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 1993;30(6):672-679.
24. Moffett JR, Ross B, Arun P, Madhavarao CN, Namboodiri AMA. N-acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog Neurobiol 2007;81(2):89-131.
25. Patel TB, Clark JB. Synthesis of N-acetyl-Laspartate by rat brain mitochondria and its involvement in mitochondrial/cytosolic carbon transport. Biochem J 1979;184(3):539-546.
26. Andres RH, Ducray AD, Schlattner U, Wallimann T, Widmer HR. Functions and effects of creatine in the central nervous system. Brain Res Bull 2008;76(4):329-343.
27. Brand A, Richter-Landsberg C, Leibfritz D. Multinuclear NMR studies on the energy metabolism of glial and neuronal cells. Dev Neurosci 1993;15(3-5):289-298.
28. Ross BD. Biochemical considerations in 1H spectroscopy: glutamate and glutamine, myo-inositol and related metabolites. NMR Biomed 1991;4(2):59-63.
29. Griffith HR, den Hollander JA, Okonkwo OC, O'Brien T, Watts RL, Marson DC. Brain N-acetylaspartate is reduced in Parkinson disease with dementia. Alzheimer Dis Assoc Disord 2008;22(1):54-60.
30. Demougeot C, Garnier P, Mossiat C, et al. N-Acetylaspartate, a marker of both cellular dysfunction and neuronal loss: its relevance to studies of acute brain injury. J Neurochem 2001;77(2):408-415.
31. Hattingen E, Magerkurth J, Pilatus U, et al. Phosphorus and proton magnetic resonance spectroscopy demonstrates mitochondrial dysfunction in early and advanced Parkinson's disease. Brain 2009;132(Pt 12):3285-3297.
32. Weiduschat N, Mao X, Beal MF, Nirenberg MJ, Shungu DC, Henchcliffe C. Usefulness of proton and phosphorus MR spectroscopic imaging for early diagnosis of Parkinson's disease. J Neuroimaging 2015;25(1):105-110.
33. Coune PG, Craveiro M, Gaugler MN, et al. An in vivo ultrahigh field 14.1 T (1) H-MRS study on 6-OHDA and a-synuclein-based rat models of Parkinson's disease: GABA as an early disease marker. NMR Biomed 2013;26(1):43-50.